2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 604

Characterisation of Mucosal-Associated Invariant T (MAIT) Cells in Ankylosing Spondylitis Patients
Abstract Number: 2806

Characteristic Phenotype of Peripheral Blood Lymphocytes in Patients with IgG4-Related Disease, Comparing to Primary Sjögren Syndrome and Healthy Controls
Abstract Number: 2245

Characteristics of Conventional Footwear and Their Association with Reductions in Knee Loading with a Flexible Footwear Intervention
Abstract Number: 707

Characteristics of Lupus Patients with Interstitial Lung Disease and Relationship with Jo-1 Antibody
Abstract Number: 2124

Characteristics of Medicare Beneficiaries Travelling Long Distances to Visit a Rheumatologist
Abstract Number: 924

Characteristics of Pain Flares in Knee Osteoarthritis
Abstract Number: 256

Characteristics of Pain in Fabry Disease
Abstract Number: 2532

Characteristics of Primary Sjögren Syndrome in the Black Population of Martinique
Abstract Number: 2498

Characteristics of Responding Versus Non-Responding Moderate Rheumatoid Arthritis Patients Treated with Etanercept Plus Methotrexate
Abstract Number: 2415

Characteristics of Rheumatoid Arthritis Patients Not Receiving Early Initiation of Disease Modifying Therapy
Abstract Number: 1065

Characteristics of Rheumatoid Arthritis Patients with and without Cardiovascular Diseases – Data from the Ontario Best Practice Research Initiative (OBRI)
Abstract Number: 2672

Characteristics of the Reproductive System in Systemic Lupus Erythematosus: A Cross-Sectional Survey with Pair-Matched Controls
Abstract Number: 1499

Characterization of ABT-494, a Second Generation Jak1 Selective Inhibitor
Abstract Number: 634

Characterization of CD4⁺ T Cell Response and Effects of Regulatory T Cells in Pristane Induced Lupus (PIL)
Abstract Number: 434

Characterization of Lung Inflammation in the Lungs of Early Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].